Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019.
Focal therapy
HIFU
Population-based
Prostate cancer
TOOKAD®
TULSA
Trends
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
23
02
2022
accepted:
22
04
2022
pubmed:
14
5
2022
medline:
30
6
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
Focal therapy (FT) offers an alternative approach for prostate cancer (PCa) treatment in selected patients. However, little is known on its actual establishment in health care reality. We defined FT as high-intensity focused ultrasound (HIFU), hyperthermia ablation, cryotherapy, transurethral ultrasound ablation (TULSA) or vascular-targeted photodynamic therapy (VTP) TOOKAD We identified 23,677 cases of FT from 2006 to 2019. Considering all PCa cases with surgery, radiotherapy or FT, the share of FT was stable at 4%. The annual caseload of FT increased to a maximum of 2653 cases in 2008 (p < 0.001) and then decreased to 1182 cases in 2014 (p < 0.001). Since 2015, the cases of FT remained on a plateau around 1400 cases per year. The share of HIFU was stable at 92-96% from 2006 to 2017 and decreased thereafter to 75% in 2019 (p = 0.015). In 2019, VTP-TOOKAD The FT development in Germany followed the Gartner hype cycle. While HIFU treatment is the most commonly performed FT, the share of newer FT modalities such as VTP-TOOKAD
Identifiants
pubmed: 35562598
doi: 10.1007/s00345-022-04024-0
pii: 10.1007/s00345-022-04024-0
pmc: PMC9236973
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1645-1652Informations de copyright
© 2022. The Author(s).
Références
Nahar B, Parekh DJ (2020) Focal therapy for localized prostate cancer: where do we stand? Eur Urol Focus 6(2):208–211. https://doi.org/10.1016/j.euf.2019.04.012
doi: 10.1016/j.euf.2019.04.012
pubmed: 31053567
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
pubmed: 30207593
Wallis CJD, Saskin R, Choo R et al (2016) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70(1):21–30
doi: 10.1016/j.eururo.2015.11.010
Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M (2007) Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 100:540–543
doi: 10.1111/j.1464-410X.2007.07009.x
van der Poel HG, van den Bergh RCN, Briers E et al (2018) Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol 74:84–91
doi: 10.1016/j.eururo.2018.01.001
Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA (2019) Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol 31(3):200–206
doi: 10.1097/CCO.0000000000000515
Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M (1995) Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 55(15):3346–3351 (PMID: 7542168)
pubmed: 7542168
Chaussy CH, Thuroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4:248–252
doi: 10.1007/s11934-003-0077-0
Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J (1993) Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 72(4):1291–1299
doi: 10.1002/1097-0142(19930815)72:4<1291::AID-CNCR2820720423>3.0.CO;2-I
Flegar L, Buerk B, Proschmann R et al (2021) Vascular-targeted photodynamic therapy in unilateral low-risk prostate cancer in Germany: 2-yr single-centre experience in a real-world setting compared with radical prostatectomy. Eur Urol Focus S2405–4569(21):00042
Chin JL, Billia M, Relle J et al (2016) Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol 70(3):447–455
doi: 10.1016/j.eururo.2015.12.029
Werntz RP, Eggener SE (2018) Novel focal therapy treatment options for prostate cancer. Curr Opin Urol 28(2):178–183
doi: 10.1097/MOU.0000000000000469
Westhoff N, Ernst R, Kowalewski KF et al (2021) Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer. World J Urol 39(4):1121–1129
doi: 10.1007/s00345-020-03301-0
Flegar L, Baunacke M, Buerk BT, et al. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ (abgerufen am: 18.01.2022)
Flegar L, Groeben C, Koch R et al (2020) Trends in renal tumor surgery in the United States and Germany between 2006 and 2014: organ preservation rate is improving. Ann Surg Oncol 27(6):1920–1928. https://doi.org/10.1245/s10434-019-08108-x
doi: 10.1245/s10434-019-08108-x
pubmed: 31823172
Groeben C, Koch R, Baunacke M, Wirth MP, Huber J (2016) Robots drive the German radical prostatectomy market: a total population analysis from 2006 to 2013. Prostate Cancer Prostatic Dis 19(4):412–416. https://doi.org/10.1038/pcan.2016.34
doi: 10.1038/pcan.2016.34
pubmed: 27549566
Oosterhoff JHF, Doornberg JN (2020) Artificial intelligence in orthopaedics: false hope or not? A narrative review along the line of Gartner’s hype cycle. EFORT Open Rev. 5(10):593–603. https://doi.org/10.1302/2058-5241.5.190092
doi: 10.1302/2058-5241.5.190092
pubmed: 33204501
pmcid: 7608572
Onik G (2004) The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review. Technol Cancer Res Treat 3(4):365–370. https://doi.org/10.1177/153303460400300406 (PMID: 15270587)
doi: 10.1177/153303460400300406
pubmed: 15270587
Fütterer JJ, Briganti A, De Visschere P et al (2015) Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68(6):1045–1053. https://doi.org/10.1016/j.eururo.2015.01.013
doi: 10.1016/j.eururo.2015.01.013
pubmed: 25656808
Valerio M, Cerantola Y, Eggener SE et al (2017) New and established technology in focal ablation of the prostate: a systematic review. Eur Urol 71:17–34
doi: 10.1016/j.eururo.2016.08.044
Hopstaken J, Bomers J, Sedelaar M, Valerio M, Fütterer J, Rovers M (2022) An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 81:5–33
doi: 10.1016/j.eururo.2021.08.005
Azzouzi AR, Vincendeau S, Barret E et al (2017) Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 18:181–191
doi: 10.1016/S1470-2045(16)30661-1
Lumiani A, Samun D, Sroka R, Muschter R (2021) Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urol Oncol 39(12):830.e9-830.e16. https://doi.org/10.1016/j.urolonc.2021.04.022
doi: 10.1016/j.urolonc.2021.04.022
Mercader C, Musquera M, Franco A, Alcaraz A, Ribal MJ (2020) Primary cryotherapy for localized prostate cancer treatment. Aging Male 23(5):1460–1466. https://doi.org/10.1080/13685538.2020.1796960 (Epub 2020 Nov 16 PMID: 33191831)
doi: 10.1080/13685538.2020.1796960
pubmed: 33191831
Fegoun AB, Barret E, Prapotnich D et al (2011) Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 37(2):213–219. https://doi.org/10.1590/s1677-55382011000200008
doi: 10.1590/s1677-55382011000200008
pubmed: 21557838
Groeben C, Koch R, Baunacke M et al (2018) Urinary diversion after radical cystectomy for bladder cancer: comparing trends in the US and Germany from 2006 to 2014. Ann Surg Oncol 25(12):3502–3509
doi: 10.1245/s10434-018-6381-1
Giordano SH, Kuo Y-F, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS (2008) Limits of observational data in determining outcomes from cancer therapy. Cancer 112:2456–2466
doi: 10.1002/cncr.23452